undamentalytics Newsletter
Sign in

Neuroone Medical Technologies Corp key statistics and ratios

In fiscal 2025, Neuroone Medical Technologies Corp had return on equity of -91.3% and a net margin of -39.6%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Dec 20132015Dec 20142016Dec 20152017Dec 20162021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Net margin−517.9%−511.4%<−999%<−999%<−999%——<−999%<−999%−607.4%−356.7%−39.6%−78.6%
Return on equity————————−123.8%−149.6%—−91.3%−137.4%
Return on assets−66.2%−240.2%−186.5%<−999%<−999%<−999%−12.6%−228.8%−96.3%−113.4%−182.9%−44.6%−87.7%
R&D as % of revenue———————>999%>999%355.5%146.7%54.8%57.0%
SG&A as % of revenue———————>999%>999%354.7%228.8%81.2%82.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $6m
Short-term assets $6mLonger-term assets $0m
What it owes, and who funded it · $6m
Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $4m
  • Short-term assets cover short-term liabilities $6m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6m short-term assets against $377,125 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Neuroone Medical Technologies Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

21 /100

Weak moat

How hard Neuroone Medical Technologies's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -175.4% of total assets over 9 years.

  • Pricing power 11 / 20

    Gross margin has been a median 55.6%, moving by 47.7 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -1402.8%; its worst year was -28241.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -290.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 1234.3% over five years; stock-based pay has been a median 32.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: MLSS vs NMTCNMTC vs WOKNMTC vs NUWENMTC vs NNNN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuroone Medical Technologies Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuroone Medical Technologies Corp.